4.7 Review

Immunotherapy of cancer

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 625, Issue 1-3, Pages 41-54

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2009.09.067

Keywords

Immunotherapy; Cancer; Monoclonal antibody; Cell-based therapy; Toll-like receptors

Funding

  1. Centers of Research Excellence [CA06927]
  2. National Cancer Institute (NCI)
  3. National Institutes of Health
  4. Fox Chase Cancer Center
  5. [CA083859]
  6. [CA100226]

Ask authors/readers for more resources

Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments. (C) 2009 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available